AGIO · ISSUER CIK 1439222
AGIOS PHARMACEUTICALS, INC.
Between Aug 1, 2026 and Oct 29, 2026, 1 AGIOS PHARMACEUTICALS, INC. insiders reported $0.00 of open-market purchases and $1.3M of sales on SEC Form 4.
↗1 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 3 of 3 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$1.3MInsider selling
−$1.3MNet open-market
Oct 28, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 28, 202616:02 | Oct 26, 2026 | AGIO | Chief Medical Officer | S · Sell10b5-1 | $37.69 | −7,866 | 54,645 | -13% | −$296K | ||
| Oct 28, 202616:02 | Oct 26, 2026 | AGIO | Chief Medical Officer | M · Exercise10b5-1 | $25.01 | +7,866 | 62,511 | +14% | $197K | ||
| Oct 23, 202616:05 | Oct 22, 2026from Oct 21, 2026 | AGIO | Chief Medical Officer | S · Sell10b5-1 | $37.53 | −1,989 | 54,645 | -4% | −$75K | ||
| Oct 23, 202616:05 | Oct 22, 2026from Oct 21, 2026 | AGIO | Chief Medical Officer | M · Exercise10b5-1 | $25.01 | +1,989 | 55,145 | +4% | $50K | ||
| Aug 6, 202616:13 | Aug 4, 2026 | AGIO | Chief Medical Officer | S · Sell10b5-1 | $30.48 | −30,000 | 54,645 | -35% | −$914K |